Nemaura Medical (NASDAQ: NMRD), a medical technology company developing and commercializing non-invasive wearable diagnostic devices, is positioned to offer innovative solutions to a rapidly growing market. According to a recent report released by the International Diabetes Federation (“IDF”), diabetes is “spiraling out of control.” According to the report, 537 million adults live with diabetes, a number projected to rise to 643 million by 2030 and 783 million by 2045. In addition to impacting the health and wellbeing of patients, employers and insurers are burdened with diabetes-related expenses, currently estimated at over $966 billion – a 316% increase over the last 15 years. “Nemaura addresses this through its flagship sugarBEAT(R) wearable CGM device and companion mobile app that provides helpful disease management insights,” reads a recent article. “Unlike other CGM devices, sugarBEAT is non-invasive and doesn’t require insertion of the sensor inside the skin: Users can now choose the days they wear the patch instead of a prolonged continuous-wear period lasting up to 14 days. Combined with MiBoKo, the company’s recently launched metabolic health program, both products provide valuable AI-powered insights that NMRD management believes will benefit one-third to half of the diabetes market.”
To view the full article, visit https://ibn.fm/foKD5
About Nemaura Medical Inc.
Nemaura is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT diabetes program that is currently undergoing pilot studies. Additionally, Nemaura has launched MiBoKo, a new program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
